Vanguard Fiduciary Trust
SNOA icon

Vanguard Fiduciary Trust’s Sonoma Pharmaceuticals SNOA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$123 Hold
100
– – ﹤0.01% 4075
2026
Q1 		$213 Buy
+100
New +$292 ﹤0.01% 4060

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $6.54B AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust's SNOA Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Sonoma Pharmaceuticals (SNOA) position steady in Q2 2026 at 100 shares worth $123. The position accounts for ﹤0.01% of the portfolio, ranked #4075.

Vanguard Fiduciary Trust first reported a position in SNOA in Q1 2026 and has held it in 2 quarters since. The position peaked at $213 in Q1 2026. 14 funds tracked by Wall St. Rank hold SNOA as of Q2 2026.

  • Vanguard Fiduciary Trust held 100 shares of Sonoma Pharmaceuticals worth $123 as of Q2 2026.
  • Vanguard Fiduciary Trust left its Sonoma Pharmaceuticals share count unchanged in Q2 2026.
  • Sonoma Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #4075 holding.
  • Vanguard Fiduciary Trust first reported a position in Sonoma Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Sonoma Pharmaceuticals position peaked at $213 in Q1 2026.
  • 14 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.